[go: up one dir, main page]

MX2019012884A - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX2019012884A
MX2019012884A MX2019012884A MX2019012884A MX2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A MX 2019012884 A MX2019012884 A MX 2019012884A
Authority
MX
Mexico
Prior art keywords
combination
proliferative disease
treatment
subject
present
Prior art date
Application number
MX2019012884A
Other languages
English (en)
Other versions
MX393855B (es
Inventor
Cooke Vesselina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62218018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019012884(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019012884A publication Critical patent/MX2019012884A/es
Publication of MX393855B publication Critical patent/MX393855B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende (a) un inhibidor de Raf conforme lo definido en la presente, o una sal farmacéuticamente aceptable del mismo y (b) un inhibidor de MEK, particularmente trametinib, particularmente para usarse en el tratamiento de una enfermedad proliferativa. La presente invención además se refiere a usos de esta combinación para la preparación de un medicamento para el tratamiento de una enfermedad proliferativa; a métodos de tratamiento de una enfermedad proliferativa en un sujeto que lo necesite que comprenden administrar a dicho sujeto una cantidad conjuntamente terapéuticamente efectiva de dicha combinación; al uso de tal combinación para el tratamiento de una enfermedad proliferativa; a composiciones farmacéuticas que comprenden tal combinación y a envases comerciales para las mismas.
MX2019012884A 2017-05-02 2018-04-30 Terapia de combinación que comprende un inhibidor de raf y trametinib MX393855B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762500108P 2017-05-02 2017-05-02
US201862656423P 2018-04-12 2018-04-12
PCT/IB2018/052989 WO2018203219A1 (en) 2017-05-02 2018-04-30 Combination therapy

Publications (2)

Publication Number Publication Date
MX2019012884A true MX2019012884A (es) 2020-01-14
MX393855B MX393855B (es) 2025-03-21

Family

ID=62218018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012884A MX393855B (es) 2017-05-02 2018-04-30 Terapia de combinación que comprende un inhibidor de raf y trametinib

Country Status (17)

Country Link
US (2) US11266653B2 (es)
EP (2) EP4272740A1 (es)
JP (3) JP7309614B2 (es)
KR (2) KR20240032157A (es)
CN (1) CN110494166B (es)
AU (1) AU2018262891B2 (es)
CA (1) CA3057969A1 (es)
CL (1) CL2019003091A1 (es)
DK (1) DK3618875T3 (es)
ES (1) ES2952265T3 (es)
FI (1) FI3618875T3 (es)
IL (2) IL311471A (es)
MX (1) MX393855B (es)
PL (1) PL3618875T3 (es)
PT (1) PT3618875T (es)
TW (1) TWI798218B (es)
WO (1) WO2018203219A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2974991T3 (es) 2016-09-19 2024-07-02 Novartis Ag Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK
FI3618875T3 (fi) * 2017-05-02 2023-07-04 Novartis Ag Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito
CA3072345A1 (en) * 2017-08-11 2019-02-14 Curematch, Inc. Drug combinations for targeting multiple mutations in cancer
KR20210105388A (ko) * 2018-12-20 2021-08-26 노파르티스 아게 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
US20230226030A1 (en) * 2020-02-18 2023-07-20 Novartis Ag Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
CA3151403A1 (en) * 2020-02-27 2021-09-02 National University Corporation Hokkaido University Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
JP2023525100A (ja) * 2020-05-12 2023-06-14 ノバルティス アーゲー Ｃｒａｆ阻害剤を含む治療的組み合わせ
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
EP4203963B1 (en) * 2020-08-31 2026-01-21 Novartis AG Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
GB2629956A (en) * 2022-01-27 2024-11-13 Univ Tohoku Therapeutic agent for cancer
TW202342766A (zh) 2022-03-02 2023-11-01 瑞士商諾華公司 用於癌症治療之精準療法
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2024088273A1 (zh) * 2022-10-25 2024-05-02 中国科学院上海药物研究所 一种萘酰胺化合物治疗kras突变相关疾病的用途
CN117919234A (zh) * 2022-10-25 2024-04-26 上海润石医药科技有限公司 一种萘酰胺化合物治疗耐药性肿瘤的用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
DE3029376A1 (de) 1980-07-31 1982-03-18 Nepera Chemical Co. Inc., Harriman, N.Y. Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
JP2722586B2 (ja) 1989-01-13 1998-03-04 大正製薬株式会社 インドリルイミダゾール誘導体
JP2808460B2 (ja) 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2001500482A (ja) 1996-08-27 2001-01-16 ノバルティス アクチェンゲゼルシャフト 除草性ｓ置換１，２，４，６―チアトリアジン類
ATE554750T1 (de) 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
BR0009721A (pt) 1999-04-15 2002-02-13 Bristol Myers Squibb Co Inibidores de tirosina quinase de proteìna cìclica
JP2000302680A (ja) 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
ATE339406T1 (de) 1999-09-23 2006-10-15 Astrazeneca Ab Chinazoline verbindungen als heilmittel
PL355912A1 (en) 1999-11-22 2004-05-31 Smithkline Beecham Plc. Novel compounds
AU2001232809A1 (en) 2000-01-18 2001-07-31 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CN1230166C (zh) 2000-01-18 2005-12-07 沃泰克斯药物股份有限公司 回旋酶抑制剂及其用途
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
ES2218391T3 (es) 2000-03-06 2004-11-16 Smithkline Beecham Plc Derivados de imidazol como inhibidores de raf-cinasa.
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
WO2001074811A2 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1300396B1 (en) 2000-06-12 2009-01-14 Eisai R&D Management Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US20040053943A1 (en) 2000-11-20 2004-03-18 Adams Jerry L. Novel compounds
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
ATE341539T1 (de) 2001-01-26 2006-10-15 Chugai Pharmaceutical Co Ltd Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
EP1364949A4 (en) 2001-02-02 2005-11-23 Takeda Pharmaceutical JNK INHIBITOR
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process
JP2002338537A (ja) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
EA007987B1 (ru) 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
RU2005106871A (ru) 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
EA200500354A1 (ru) 2002-09-18 2005-10-27 Пфайзер Продактс Инк. Новые оксазольные и тиазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
ATE433968T1 (de) 2002-09-18 2009-07-15 Pfizer Prod Inc Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf)
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2005034869A2 (en) 2003-10-08 2005-04-21 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2542653A1 (en) 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
JP5095216B2 (ja) 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド アリールイミダゾールおよびその抗癌剤としての使用
JP4853284B2 (ja) 2004-03-05 2012-01-11 大正製薬株式会社 チアゾール誘導体
KR100749566B1 (ko) 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
PL2298768T3 (pl) 2004-06-11 2013-03-29 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
EP1786802A1 (en) 2004-08-31 2007-05-23 Biogen Idec MA, Inc. Pyrimidinylimidazoles as tgf-beta inhibitors
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
AU2005295734A1 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
JP2007246520A (ja) 2006-02-15 2007-09-27 Takeda Yuichiro Ｒａｇｅ阻害剤
EP2007393B1 (en) 2006-04-07 2013-08-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
US8022205B2 (en) 2006-08-08 2011-09-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivatives as PI3K inhibitor and use thereof
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
RU2479580C2 (ru) 2007-06-27 2013-04-20 Астразенека Аб Производные пиразинона и их применение для лечения легочных заболеваний
CN101743242A (zh) 2007-06-29 2010-06-16 苏尼西斯制药有限公司 用作raf激酶抑制剂的杂环化合物
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
US20100240657A1 (en) 2007-07-02 2010-09-23 Boehringer Ingelheim International Gmbh Chemical compounds
CN101796048A (zh) 2007-07-09 2010-08-04 阿斯利康(瑞典)有限公司 用于治疗增殖病症的三取代的嘧啶衍生物
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
US8293747B2 (en) 2007-07-19 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
US20110190280A1 (en) 2007-08-29 2011-08-04 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
WO2009030952A2 (en) 2007-09-05 2009-03-12 Astrazeneca Ab Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
MX2010010317A (es) 2008-03-21 2010-10-04 Novartis Ag Compuestos heterociclicos novedosos y usos de los mismos.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
KR20110017432A (ko) 2008-06-11 2011-02-21 아이알엠 엘엘씨 말라리아의 치료에 유용한 화합물 및 조성물
WO2010010154A1 (en) 2008-07-24 2010-01-28 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
CA2734802C (en) 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
BRPI0924084B1 (pt) 2008-12-19 2021-12-21 Vertex Pharmaceuticals Incorporated Derivados de pirazina e composição farmacêutica que os compreende
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2011026911A1 (en) 2009-09-04 2011-03-10 Novartis Ag Bipyridines useful for the treatment of proliferative diseases
WO2011059610A1 (en) 2009-11-10 2011-05-19 Glaxosmithkline Llc Benzene sulfonamide thiazole and oxazole compounds
PL2520575T3 (pl) 2009-12-28 2017-05-31 General Incorporated Association Pharma Valley Project Supporting Organization Związek 1,3,4-oksadiazolo-2-karboksyamidowy
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
EP2585454A1 (en) 2010-06-25 2013-05-01 Novartis AG Heteroaryl compounds and compositions as protein kinase inhibitors
WO2012027438A1 (en) 2010-08-26 2012-03-01 Glaxosmithkline Llc Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
CN101993415B (zh) 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
HUE040136T2 (hu) 2011-02-07 2019-02-28 Plexxikon Inc Vegyületek és eljárások kináz modulációra és azok indikációi
EP2686317A4 (en) 2011-03-17 2014-08-20 Selexagen Therapeutics Inc RAF KINASE INHIBITORS
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN103797011B (zh) 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
BR112014006743A8 (pt) 2011-09-21 2018-01-09 Cellzome Ltd composto, uso de um composto, e, método para tratar, controlar, retardar ou impedir uma ou mais condições
AU2013255437A1 (en) 2012-05-02 2014-11-13 Lupin Limited Substituted pyridine compounds as CRAC modulators
JP6078640B2 (ja) 2012-05-15 2017-02-08 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
WO2014008214A1 (en) 2012-07-02 2014-01-09 Biogen Idec Ma Inc. Biaryl-containing compounds as inverse agonists of ror-gamma receptors
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
UA115786C2 (uk) 2012-08-07 2017-12-26 Новартіс Аг ФАРМАЦЕВТИЧНА КОМБІНАЦІЯ, ЩО МІСТИТЬ ІНГІБІТОР B-Raf, ІНГІБІТОР EGFR ТА, НЕОБОВ'ЯЗКОВО, ІНГІБІТОР РІ3K-?
BR112015004578A2 (pt) 2012-09-04 2017-07-04 Glaxosmithkline Llc métodos para fornecer tratamento adjuvante a um paciente com uma diagnose anterior de melanoma que foi ressectado e para aumentar sobrevivência sem recaída (rfs) de um paciente depois de ressecção de melanoma, e, composição
WO2014052699A1 (en) 2012-09-28 2014-04-03 Cephalon, Inc. Azaquinazoline inhibitors of atypical protein kinase c
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
ES2676177T3 (es) 2012-12-20 2018-07-17 Novartis Ag Una combinación farmacéutica que comprende binimetinib
US9242969B2 (en) * 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JP6449234B2 (ja) 2013-03-21 2019-01-09 ノバルティス アーゲー 併用療法
CA2922532C (en) 2013-11-01 2023-09-19 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
WO2015095819A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN107074828B (zh) 2014-09-12 2020-05-19 诺华股份有限公司 用作raf激酶抑制剂的化合物和组合物
ES2844211T3 (es) 2014-09-12 2021-07-21 Novartis Ag Compuestos y composiciones en calidad de inhibidores de quinasa
WO2016115376A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Of California Detection and treatment of double drug resistant melanomas
NZ735715A (en) 2015-04-15 2022-09-30 Beigene Ltd Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
AU2016292762B2 (en) 2015-07-10 2022-07-28 Genmab A/S AXL-specific antibody-drug conjugates for cancer treatment
CN108348514A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
CN108348513A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 用于治疗或预防癌症的ribociclib与达拉菲尼的组合
WO2017210538A1 (en) 2016-06-03 2017-12-07 Giordano Caponigro Pharmaceutical combinations
AU2017279046B2 (en) 2016-06-10 2020-07-02 Novartis Ag Therapeutic uses of a c-Raf inhibitor
ES2974991T3 (es) * 2016-09-19 2024-07-02 Novartis Ag Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK
WO2018107146A1 (en) 2016-12-11 2018-06-14 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of braf mutant cancers
FI3618875T3 (fi) * 2017-05-02 2023-07-04 Novartis Ag Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito
EP3624896A4 (en) 2017-05-16 2021-03-31 Biomed Valley Discoveries, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS
JP7530829B2 (ja) 2017-09-08 2024-08-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法
TW202023556A (zh) 2018-08-27 2020-07-01 美商庫拉腫瘤技術股份有限公司 以mapk路徑抑制劑治療腺癌
KR20210105388A (ko) 2018-12-20 2021-08-26 노파르티스 아게 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
US20230226030A1 (en) 2020-02-18 2023-07-20 Novartis Ag Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
JP2023525100A (ja) 2020-05-12 2023-06-14 ノバルティス アーゲー Ｃｒａｆ阻害剤を含む治療的組み合わせ
EP4203963B1 (en) 2020-08-31 2026-01-21 Novartis AG Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma

Also Published As

Publication number Publication date
JP2023145467A (ja) 2023-10-11
AU2018262891A1 (en) 2019-10-17
KR20240032157A (ko) 2024-03-08
TW201842914A (zh) 2018-12-16
US20200246346A1 (en) 2020-08-06
FI3618875T3 (fi) 2023-07-04
PT3618875T (pt) 2023-08-07
KR102641827B1 (ko) 2024-03-04
PL3618875T3 (pl) 2023-10-23
JP7520189B2 (ja) 2024-07-22
EP3618875A1 (en) 2020-03-11
US11266653B2 (en) 2022-03-08
RU2019134757A3 (es) 2021-08-17
CL2019003091A1 (es) 2020-02-07
KR20190141164A (ko) 2019-12-23
US20220143036A1 (en) 2022-05-12
RU2019134757A (ru) 2021-06-02
CN110494166A (zh) 2019-11-22
JP2020518568A (ja) 2020-06-25
US12036227B2 (en) 2024-07-16
TWI798218B (zh) 2023-04-11
IL311471A (en) 2024-05-01
BR112019022511A2 (pt) 2020-05-12
MX393855B (es) 2025-03-21
ES2952265T3 (es) 2023-10-30
CA3057969A1 (en) 2018-11-08
WO2018203219A1 (en) 2018-11-08
JP7309614B2 (ja) 2023-07-18
DK3618875T3 (da) 2023-07-10
IL270224B1 (en) 2024-04-01
EP3618875B1 (en) 2023-04-05
JP2024160223A (ja) 2024-11-13
EP4272740A1 (en) 2023-11-08
AU2018262891B2 (en) 2021-04-01
IL270224A (es) 2019-12-31
CN110494166B (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
MX2019012884A (es) Terapia de combinacion.
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
MX2019009443A (es) Metodos para tratar la influenza.
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
EA033298B1 (ru) Комбинированная лекарственная форма тезофензина и метопролола
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
AR108792A1 (es) Composiciones que comprenden timolol